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Abstract
Clinical evidence suggests that gemcitabine (Gem) plus oxaliplatin (Ox) is superior to gemcitabine alone in ad-
vanced pancreatic carcinoma. The addition of radiation to gemcitabine improves response and is a standard treat-
ment for locally advanced disease. We investigated the effect of oxaliplatin on gemcitabine-based chemoradiation
by determining whether gemcitabine and oxaliplatin produced synergistic cytotoxicity using median effect analysis
and radiosensitization using clonogenic survival assays. We analyzed the effects of gemcitabine and oxaliplatin
on cell cycle distribution by DNA content and on radiation-induced DNA damage repair by phosphorylated H2AX
(γ-H2AX). Gemcitabine and oxaliplatin produced schedule-dependent synergistic cytotoxicity in BxPC-3 and Panc-1 cells
(combination indices: 0.76 ± 0.05, 0.61 ± 0.11). In BxPC-3 cells, oxaliplatin did not affect gemcitabine-mediated
radiosensitization (Gem 1.99 ± 0.27; Gem + Ox 2.38 ± 0.30). In Panc-1 cells, oxaliplatin significantly enhanced
gemcitabine-mediated radiosensitization (Gem1.31±0.05; Gem+Ox 2.90±0.31). Radiosensitization by gemcitabine
was accompanied by early S-phase arrest and induction/persistence of γ-H2AX protein, which were unaltered by
oxaliplatin. Addition of oxaliplatin to gemcitabineproduces radiosensitizationequal toor greater thangemcitabine alone,
supporting our clinical investigation of oxaliplatin with gemcitabine–radiation in pancreatic cancer aimed at improving
systemic disease control while maintaining local tumor radiosensitization.
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Introduction
In the past decade, gemcitabine has become the standard therapy for
advanced pancreatic cancer. The combination of concurrent highly
conformal radiation with gemcitabine produces a median survival
of 12 months [1] that compares favorably to historical controls
of gemcitabine alone with a median survival of 7 months [2].
Although local tumor control is an important issue, the majority
of treatment failures is due to systemic disease progression [3].
Therefore, our approach in designing clinical trials for pancreatic
cancer has emphasized on improving systemic disease control while
maintaining local tumor control. This approach led us to combine
gemcitabine with radiation, because gemcitabine has been found to
be more effective than 5-FU for patients with locally advanced or
metastatic pancreas cancer [2] and because gemcitabine is a potent
radiation sensitizer in pancreatic cancer cells [4]. Our initial clinical
studies established the maximum safe dose of radiation (36 Gy in
2.4-Gy fractions) that could be used with full-dose (1000 mg/m2)
gemcitabine and suggested that gemcitabine radiation therapy was
at least equal to if not better than 5-FU–radiation therapy [1,5].
While we were pursuing the combination of gemcitabine and ra-
diation for locally advanced pancreatic cancer, others were combining
gemcitabine with cisplatin in effort to improve therapy for metastatic
pancreatic cancer. Philip et al. [6] demonstrated that cisplatin could
be safely administered with full-dose gemcitabine and that it po-
tentially could improve median survival. These studies led us to
combine a gemcitabine–cisplatin–based chemotherapy regimen with
radiation. Our preclinical studies showed that gemcitabine and
cisplatin produced synergistic cytotoxicity without compromising
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radiosensitization compared to gemcitabine alone [7]. This preclini-
cal data led us to initiate a clinical trial combining gemcitabine, cis-
platin, and radiation. This study suggested that the full systemic dose
of cisplatin and gemcitabine could be administered in combination
with conformal tumor (as well as involved regional lymph nodes)
radiation and that this combination may provide additional benefit
beyond that offered by gemcitabine and radiation [8]. The patient
survival in this clinical trial of 13 months seemed promising com-
pared to historical controls for gemcitabine–radiation therapy; how-
ever, increased systemic toxicity caused by the addition of cisplatin
was noted.
Therefore, we and others became interested in the platinum ana-
logue, oxaliplatin, which appears to have equal efficacy to cisplatin
but less gastrointestinal, hematological, and renal toxicity. Clinical
trials combining gemcitabine plus oxaliplatin versus gemcitabine
alone in metastatic or locally unresectable disease demonstrated that
the combination was significantly superior (P < .05) with regard to re-
sponse (27% vs 17%), progression-free survival (5.8 vs 3.7 months),
and clinical benefit (38% vs 27%), although the improvement in
overall survival did not reach significance (median of 9 vs 7.1 months,
P = .13) [9].
Based on these data suggesting that the combination gemcitabine
with cisplatin or oxaliplatin is superior to gemcitabine alone, we
wished to conduct a preclinical study combining gemcitabine and
oxaliplatin with radiation. We designed our study to first determine
whether gemcitabine and oxaliplatin could produce synergistic cyto-
toxicity. We then went on to assess radiosensitization in response to
gemcitabine and oxaliplatin.
Materials and Methods
Cell Lines and Drug Solutions
The human pancreatic adenocarcinoma cell lines BxPC-3 and
Panc-1 were obtained from American Type Culture Collection
(Manassas, VA) and maintained in either RPMI 1640 or Dulbecco's
modified Eagle's medium, respectively, with 10% Cosmic Calf Se-
rum (Hyclone, Logan, UT) and antibiotics at 37°C in 5% CO2.
Gemcitabine (a gift from Eli Lilly, Indianapolis, IN) and oxaliplatin
(Sigma Chemical, St. Louis, MO) were dissolved in phosphate-buffered
saline (PBS) and stored at −20°C.
Clonogenic Cell Survival Assay
Clonogenic assays were performed using standard techniques as
described previously [10]. Drug cytotoxicity was calculated as the
ratio of surviving drug-treated cells relative to untreated controls.
Radiation survival data from drug-treated cells were corrected for
plating efficiency using an unirradiated plate treated with drug under
the same conditions. Cell survival curves were fitted using the linear-
quadratic equation and the mean inactivation dose was calcu-
lated according to the method of Fertil et al. [11]. The cell survival
enhancement ratio was calculated as the ratio of the mean inactiva-
tion dose under control conditions divided by the mean inactivation
dose after drug exposure. A value greater than 1 indicates signifi-
cant radiosensitization.
Combined Drug Effect Analysis
To examine synergy between gemcitabine and oxaliplatin, the sur-
vival of BxPC-3 or Panc-1 cells in response to fixed ratios of variable
doses of gemcitabine (0.1–3 or 1–30 μM, respectively) and/or oxa-
liplatin (3–60 μM) (both toxic and nontoxic) was examined using
the median effect analysis as described previously [12]. Because this
experimental design requires the two drugs be administered in a fixed
ratio, the dose of the combination required to produce fractional sur-
vival could be divided into the component doses D1 and D2 of drugs
1 and 2, respectively. The combination index (CI) was calculated ac-
cording to the equation: CI = (D1/Dx1) + (D2/Dx2) + α(D1D2) /
(Dx1Dx2) where Dx1 and Dx2 are the concentrations of drugs 1 and
2, when used alone that produce a surviving fraction of x, and D1
and D2 are the individual concentrations of drugs 1 and 2 in the
fixed ratio, which produces a surviving fraction of x: α = 1 or 0 de-
pending on whether the drugs are assumed to be mutually nonexclu-
sive or mutually exclusive, respectively. Because the sigmoidicity of
the dose–effect curves for gemcitabine and oxaliplatin is different,
α = 1 in this study. Synergy is indicated by CI < 1, additivity by
CI = 1, and antagonism by CI > 1 [12].
Irradiation
Irradiations were carried out using an X-ray unit (Pantak Therapax
DXT 300; Pantak, East Haven, CT) at a dose rate of approximately
3 Gy/min. Dosimetry was carried out using an ionization chamber
connected to an electrometer system that is directly traceable to a Na-
tional Institute of Standards and Technology calibration.
Flow Cytometry
Cells were trypsinized, washed, and resuspended in PBS, fixed by
dropwise addition of ice-cold 70% ethanol, and stored at 4°C until the
Figure 1. Combination indices of gemcitabine and oxaliplatin.
Panc-1 cells were treated with various concentrations of gemcita-
bine or oxaliplatin at a fixed ratio of 1 gemcitabine to 10 oxaliplatin
according to schedule 1 or 2. The combination indices were then
calculated as described in the Materials and Methods section at
surviving fractions between 0.5 and 0.01. Data are the mean of
n = 3 to 5 independent experiments.
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day of analysis. Cells were then washed with PBS and suspended in PBS
containing 18 μg/ml propidium iodide and 40 μg/ml ribonuclease A.
Human lymphocytes were included as internal standards. Cells were
analyzed on a FACScan flow cytometer (Becton-Dickinson, Palo Alto,
CA) with WinMDI software (Version 2.8; J. Trotter, Scripps Research
Institute, La Jolla, CA).
Immunoblot Analysis
Whole-cell lysates were prepared in buffer containing 10 mmol/l Tris
(pH 7.4), 2% sodium dodecyl sulfate, 1× Complete Protease Inhibitor
Cocktail (Roche, Mannheim, Germany), 1 mmol/l sodium fluoride,
2 mmol/l sodium orthovanadate, and 1 mmol/l sodium pyrophosphate.
Protein concentration was determined with the Bicinchoninic Acid
Protein Assay Reagent (Pierce, Rockford, IL). Samples were diluted
in loading buffer (0.32 mol/l Tris–HCl, 10% glycerol, 2% sodium
dodecyl sulfate, 0.2% bromophenol blue, and 4% 2-mercaptoethanol,
pH 6.8) and resolved on 4% to 12% gradient Bis–Tris gels (Invitrogen,
Carlsbad, CA). Separated proteins were transferred to polyvinylidene
fluoride membranes (Millipore, Bedford, MA) and hybridized overnight
at 4°C with antibodies recognizing phosphorylated H2AX (Ser139)
(γ-H2AX) (Upstate Biotechnology, Lake Placid, NY) or β-actin (Sigma).
Membranes were then probed with secondary antibodies, incubated
with an electrochemiluminescent reagent (ECL Plus; Amersham Bio-
sciences, Little Chalfont, Buckinghamshire, UK), and exposed to film.
The ImageJ program (National Institutes of Health, Bethesda, MD)
was used for the quantification of the specific protein bands on film.
Table 1. Combination Indices of Gemcitabine and Oxaliplatin at Surviving Fractions of 0.1
and 0.03.
Fraction Unaffected 0.1 0.03
BxPC-3
Schedule 1 1.22 ± 0.22 0.76 ± 0.05*
Schedule 2 1.12 ± 0.44 1.64 ± 0.49
Panc-1
Schedule 1 0.91 ± 0.10 0.83 ± 0.09
Schedule 2 0.65 ± 0.15 0.61 ± 0.11*
Data are the mean of n = 3 to 5 independent experiments ± standard error.
*P < .05, statistically significant difference from 1.
Figure 2. The effects of gemcitabine and oxaliplatin on radiosensitization. (A and C) BxPC-3 or (B and D) Panc-1 cells were treated with
the indicated concentrations of gemcitabine (Gem) or oxaliplatin (Ox) according to (A–D) schedule 1 or (C and D) schedule 2. Data are
from a single representative experiment for each cell type with each condition performed in triplicate (A and B). Alternatively, the mean
radiation enhancement ± standard error for three to six independent experiments is shown (C and D). Statistically significant differences
from radiation alone (equal to 1) (*) or gemcitabine plus radiation (**) are indicated, where P < .05.
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Statistics
Data are expressed as the mean of at least three experiments, unless
otherwise indicated. Statistically significant differences were deter-
mined using Student's t test. Statistical significance was defined at
P < .05.
Results
To determine how to combine gemcitabine and oxaliplatin with
radiation, we first wished to assess the effects of gemcitabine and ox-
aliplatin on cytotoxicity. We analyzed the clonogenic survival of BxPC-3
and Panc-1 cells in response to two different schedules of gemcitabine
and oxaliplatin according to the principles of median effect analysis to
determine whether the selected conditions produced synergistic cell kill-
ing. For gemcitabine, cells were incubated for a 2-hour period, which
should be an adequate duration for gemcitabine to deplete deoxyribo-
nucleotide triphosphate pools [13]. For oxaliplatin, cells were incubated
for 3 hours, a period sufficient for the formation of platinum-DNA ad-
ducts [14]. We investigated two different schedules: gemcitabine first
followed the next day by oxaliplatin (schedule 1) or oxaliplatin first fol-
lowed the next day by gemcitabine (schedule 2). Schedules were selected
in order to minimize (schedule 1) or maximize (schedule 2) the poten-
tial influence of oxaliplatin on gemcitabine-mediated radiosensitization.
In both of these schedules, radiation was given 24 hours after gemcita-
bine, conditions known to produce radiosensitization. To assess each of
these schedules, we examined cell survival in response to gemcitabine
and oxaliplatin. We chose a ratio of 1 part gemcitabine to 10 parts ox-
aliplatin based on clinical data demonstrating that standard chemother-
apeutic doses of these two drugs result in substantially higher plasma
concentrations of oxaliplatin relative to gemcitabine [15]. Because we
were trying to model full chemotherapeutic doses of these drugs as
used clinically, we focused on concentrations of gemcitabine and oxali-
platin that produced substantial cytotoxicity. The CI plot of Panc-1
cells treated under schedule 2 was < 1 at surviving fractions of < 0.4
(Figure 1) and reached statistical significance at a surviving fraction of
0.03 (Table 1), indicating synergistic cytotoxicity between gemcitabine
and oxaliplatin. In BxPC-3 cells, whereas schedule 2 produced only ad-
ditive cell killing, schedule 1 resulted in synergistic cell killing in response
to the combination of gemcitabine and oxaliplatin at a surviving fraction
of 0.03. From these data, we conclude that gemcitabine and oxali-
platin can promote synergistic cell killing in pancreatic cancer cells.
Based on these findings, we performed subsequent experiments to de-
termine whether oxaliplatin affected survival in response to gemcitabine
and radiation.
It was important to determine whether the combination of oxali-
platin with gemcitabine produced radiosensitization at least equal to
that of gemcitabine alone. Because radiosensitization by gemcitabine
occurs over a range of concentrations, we examined two different lev-
els of cytotoxicity. In BxPC-3 cells treated under schedule 1 and low
drug doses (0.1 μM Gem, 1 μM Ox), gemcitabine alone or in com-
bination with oxaliplatin produced modest radiosensitization (enhance-
ment ratios 1.2 ± 0.09 and 1.4 ± 0.02, respectively; Figure 2C and
Table 2). Radiosensitization was dose-dependent as a higher gemcita-
bine concentration (0.3 μM) either alone or in combination with ox-
aliplatin (3 μM) produced greater radiosensitization under both drug
treatment schedules 1 and 2 (Figure 2, A and C ). It is important to
note that oxaliplatin did not decrease gemcitabine-radiosensitization, re-
gardless of exposure condition. In the Panc-1 cell line, gemcitabine
alone produced only modest radiosensitization (Figure 2, B and D).
However, the addition of oxaliplatin (10 μM) to gemcitabine under
schedules 1 and 2 produced a marked increase in radiosensitization.
Cytotoxicity did not appear to contribute to radiosensitization, as oxa-
liplatin alone produced cytotoxicity without radiosensitization. Taken
together, these results show that oxaliplatin does not diminish gemcita-
bine-radiosensitization and that oxaliplatin can enhance gemcitabine-
radiosensitization under some conditions.
Given the importance of early S-phase cell cycle arrest in gemcita-
bine-mediated radiosensitization [16], we next analyzed the effects of
gemcitabine and oxaliplatin on cell cycle distribution. In BxPC-3
cells, early S-phase accumulation was observed 24 hours after gemci-
tabine exposure, with higher concentrations of gemcitabine (0.3 μM)
producing a sharper early S-phase arrest (Figure 3A). Oxaliplatin
alone under either treatment schedule did not produce any changes
in cell cycle distribution. In addition, the combination of oxaliplatin
with gemcitabine in either sequence (schedule 1 or 2) produced cell
cycle effects similar to gemcitabine alone. These observations in the
BxPC-3 cells were further supported by similar results in the Panc-1
cells where gemcitabine produced early S-phase arrest that was not
affected by oxaliplatin (Figure 3B). These data demonstrate that ox-
aliplatin treatment does not abrogate the early S-phase arrest in re-
sponse to gemcitabine. Furthermore, these findings suggest that whereas
the early S-phase arrest produced by gemcitabine is related to radiosen-
sitization, cell cycle alterations do not account for the increased radio-
sensitization observed in response to gemcitabine and oxaliplatin.
To explore the mechanism underlying radiosensitization in response
to gemcitabine and oxaliplatin, we assessed the effects on radiation-
induced DNA damage response. The levels of γ-H2AX were used
as a surrogate for unrepaired DNA damage. In these experiments,
BxPC-3 or Panc-1 cells treated with gemcitabine and/or oxaliplatin
(schedule 1) were irradiated and the γ-H2AX remaining 24 hours after
radiation was determined. We found in BxPC-3 cells that γ-H2AX
was elevated in response to each of the drugs alone as well as radiation
Table 2. Radiosensitization and Cytotoxicity in Response to Gemcitabine and Oxaliplatin.
Condition Radiation Enhancement Surviving Fraction
BxPC-3
0.1 μM Gem, schedule 1 1.23 ± 0.09 0.62 ± 0.13
1 μM Ox, schedule 1 1.11 ± 0.06 0.91 ± 0.01
Gem + Ox, schedule 1 1.40 ± 0.02 0.81 ± 0.28
0.3 μM Gem, schedule 1 1.99 ± 0.27 0.39 ± 0.08
3 μM Ox, schedule 1 1.17 ± 0.29 0.59 ± 0.06
Gem + Ox, schedule 1 2.38 ± 0.30 0.14 ± 0.02
0.1 μM Gem, schedule 2 1.23 ± 0.09 0.62 ± 0.13
1 μM Ox, schedule 2 0.86 ± 0.09 0.80 ± 0.23
Gem + Ox, schedule 2 1.23 ± 0.27 0.30 ± 0.12
0.3 μM Gem, schedule 2 1.99 ± 0.27 0.39 ± 0.08
3 μM Ox, schedule 2 1.01 ± 0.14 0.65 ± 0.24
Gem + Ox, schedule 2 1.83 ± 0.27 0.45 ± 0.02
Panc-1
0.3 μM Gem, schedule 1 1.18 ± 0.13 1.07 ± 0.23
3 μM Ox, schedule 1 1.04 ± 0.19 0.76 ± 0.28
Gem + Ox, schedule 1 1.39 ± 0.42 0.57 ± 0.14
1 μM Gem, schedule 1 1.31 ± 0.05 0.71 ± 0.07
10 μM Ox, schedule 1 1.38 ± 0.35 0.08 ± 0.05
Gem + Ox, schedule 1 2.90 ± 0.31 0.04 ± 0.02
0.3 μM Gem, schedule 2 1.18 ± 0.13 1.07 ± 0.23
3 μM Ox, schedule 2 1.70 ± 0.47 0.77 ± 0.16
Gem + Ox, schedule 2 1.51 ± 0.11 0.80 ± 0.08
1 μM Gem, schedule 2 1.31 ± 0.05 0.71 ± 0.07
10 μM Ox, schedule 2 1.01 ± 0.07 0.18 ± 0.00
Gem + Ox, schedule 2 1.91 ± 0.32 0.21 ± 0.03
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alone (Figure 4A). The combination of gemcitabine and/or oxaliplatin
with radiation did not cause persistence of γ-H2AX. In contrast, in the
Panc-1 cells, we only observed elevation of residual γ-H2AX in re-
sponse to gemcitabine (alone or in combination with oxaliplatin or
radiation) (Figure 4B). These results demonstrate that a 2-hour expo-
sure to gemcitabine produces a prolonged DNA damage response [17].
However, it did not appear that gemcitabine or oxaliplatin affected the
γ-H2AX in response to radiation suggesting that radiosensitization by
gemcitabine/oxaliplatin is mediated by mechanisms other than inhibi-
tion of DNA repair.
Discussion
In this study, we have found that the addition of oxaliplatin to
gemcitabine-based chemoradiation produces radiosensitization equal to
or greater than gemcitabine alone in a pancreatic cancer model. Because
the majority of pancreatic cancer treatment failures after gemcitabine–
radiotherapy are due to systemic disease progression and gemcitabine–
oxaliplatin chemotherapy has already been shown superior to gemcita-
bine alone for metastatic disease [9], we designed a preclinical study
within the context of our clinical goal of improving systemic disease
control while maintaining local control (radiosensitization). We found
Figure 3. The effects of gemcitabine and oxaliplatin on cell cycle distribution. (A) BxPC-3 or (B) Panc-1 cells were treated with the in-
dicated concentrations of gemcitabine (Gem) or oxaliplatin (Ox) according to schedule 1 or 2, as indicated. At the end of the drug treat-
ment schedules cells were analyzed for DNA content. The percentage of cells in S-phase is indicated. Human lymphocytes were
included as an internal control. Data shown are from a single experiment representative of at least three independent experiments.
40 Radiotherapy with Gemcitabine and Oxaliplatin Morgan et al. Translational Oncology Vol. 1, No. 1, 2008
that gemcitabine and oxaliplatin could produce synergistic cytotoxicity
in pancreatic cancer cells. The addition of oxaliplatin to gemcitabine–
radiation did not compromise radiosensitization by gemcitabine and,
in some conditions, enhanced it. These findings support the clinical in-
vestigation of oxaliplatin in combination with gemcitabine–radiotherapy
for locally advanced pancreatic cancer.
A number of efforts have been made to improve gemcitabine-based
chemoradiotherapy for pancreatic cancer by adding other chemother-
apeutic agents. In our previous work, we conducted preclinical and
clinical studies combining cisplatin with gemcitabine–radiation. This
Phase I trial suggested that the addition of cisplatin to gemcitabine–
radiation therapy might improve overall survival (13 months) however
patients experienced increased toxicity [8]. Some trials have combined
5-FU with gemcitabine–radiotherapy producing unacceptable toxic-
ity [18] but in others using a lower dose of radiation (45–50 Gy)
and smaller fields producing promising results with median survivals
of 14 months [19]. The combination of paclitaxel with gemcitabine–
radiotherapy has also been tested in Phase I clinical trials [20] and
Phase II trials are underway. Irinotecan has been used in an effort to
improve on gemcitabine–radiotherapy. The addition of induction iri-
notecan to gemcitabine–radiotherapy produced only a slight improve-
ment in overall survival [21]. Together, these studies indicate that
combining additional chemotherapeutic agents with gemcitabine–
radiation can increase the therapeutic efficacy if additional toxicity can
be avoided.
Molecularly targeted agents are attractive candidates for combin-
ing with gemcitabine–radiation because they typically do not possess
the cytotoxicity associated with standard chemotherapeutic agents.
Recently, a randomized Phase III clinical trial in pancreatic cancer
demonstrated a modest but statistically significant improvement in
Figure 3. (continued).
Translational Oncology Vol. 1, No. 1, 2008 Radiotherapy with Gemcitabine and Oxaliplatin Morgan et al. 41
overall survival of 6.2 vs 5.9 months in patients treated with gemcita-
bine plus erlotinib versus gemcitabine alone [22]. The results of this
trial support the clinical investigation of erlotinib with gemcitabine–
radiation. A Phase I study of gemcitabine- and paclitaxel-based chemo-
radiation with erlotinib has recently been completed and demonstrated
promising activity with a median survival of 14 months [23].
Whereas the majority of gemcitabine–radiation treatment failures
are due to systemic disease progression, local tumor control is still crit-
ical in the management of pancreatic cancer both in terms of palliative
care as well as survival [3]. Although within the context of the present
study we have focused on systemic disease control, local tumor control
should not be overlooked. As new treatment strategies increase the ef-
ficacy of systemic disease control, local tumor control will become a
greater issue. Given the severe toxicity of full-dose chemotherapy with
large field radiation [24–26], it seems reasonable to investigate the use
of IMRTwith smaller radiation fields to optimize local tumor control
when combining new agents with gemcitabine–radiation.
Based on the present study and others [9], we have initiated a clin-
ical trial combining oxaliplatin with gemcitabine–radiotherapy for
patients with pancreatic cancer. This trial is designed to determine
the dose of oxaliplatin that can be added to full-dose gemcitabine
and radiation therapy. The initial results of this study indicate that
oxaliplatin can be safely combined with gemcitabine–radiation with
promising efficacy, but the determination of the efficacy of this ap-
proach will require further study.
References
[1] McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith
DC, Brown D, Hejna G, Strawderman M, Normolle D, et al. (2001). Phase
I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine
in patients with advanced pancreatic cancer. J Clin Oncol 19, 4202–4208.
[2] Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, and Schilsky R
(1999). An investigational new drug treatment program for patients with gem-
citabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85,
1261–1268.
[3] Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS,
and Ben-Josef E (2007). Full-dose gemcitabine and concurrent radiotherapy for
unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68, 801–808.
[4] Lawrence TS, Chang EY, Hahn TM, Hertel LW, and Shewach DS (1996).
Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine.
Int J Radiat Oncol Biol Phys 34, 867–872.
[5] Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt
AJ, Weiland LH, Childs DS, Holbrook MA, et al. (1981). Therapy of locally un-
resectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads)
radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose
radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48,
1705–1710.
[6] Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun
LK, Adsay V, Weaver D, and Shields AF (2001). Phase II study of gemcitabine
and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
Cancer 92, 569–577.
[7] Symon Z, Davis M, McGinn CJ, Zalupski MM, and Lawrence TS (2002).
Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic
cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 53,
140–145.
[8] Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, and
Zalupski MM (2004). Phase I trial using a time-to-event continual reassessment
strategy for dose escalation of cisplatin combined with gemcitabine and radiation
therapy in pancreatic cancer. J Clin Oncol 22, 238–243.
[9] Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni
A, Ducreux M, Aitini E, Taieb J, et al. (2005). Gemcitabine in combination
with oxaliplatin compared with gemcitabine alone in locally advanced or meta-
static pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
J Clin Oncol 23, 3509–3516.
[10] Lawrence TS (1988). Ouabain sensitizes tumor cells but not normal cells to
radiation. Int J Radiat Oncol Biol Phys 15, 953–958.
[11] Fertil B, Dertinger H, Courdi A, and Malaise EP (1984). Mean inactivation
dose: a useful concept for intercomparison of human cell survival curves. Radiat
Res 99, 73–84.
[12] Chou TC and Talalay P (1984). Quantitative analysis of dose–effect relation-
ships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme
Regul 22, 27–55.
[13] Heinemann V, Hertel LW, Grindey GB, and Plunkett W (1988). Comparison
of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and
1-beta-d-arabinofuranosylcytosine. Cancer Res 48, 4024–4031.
[14] Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV,
Raymond E, Chaney SG, Vaisman A, Varchenko M, et al. (2000). Oxaliplatin-
induced damage of cellular DNA.Mol Pharmacol 58, 920–927.
[15] Pappas P, Mavroudis D, Nikolaidou M, Georgoulias V, and Marselos M (2006).
Coadministration of oxaliplatin does not influence the pharmacokinetics of
gemcitabine. Anticancer Drugs 17, 1185–1191.
[16] Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, and Lawrence
TS (2005). Role of checkpoint kinase 1 in preventing premature mitosis in re-
sponse to gemcitabine. Cancer Res 65, 6835–6842.
[17] Ewald B, Sampath D, and Plunkett W (2007). H2AX phosphorylation marks
gemcitabine-induced stalled replication forks and their collapse upon S-phase
checkpoint abrogation. Mol Cancer Ther 6, 1239–1248.
[18] Talamonti MS, Catalano PJ, VaughnDJ,Whittington R, Beauchamp RD, Berlin J,
and Benson AB III (2000). Eastern Cooperative Oncology Group phase I trial of
protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent
radiation therapy in patients with locally advanced pancreas cancer: a regimen with
unexpected early toxicity. J Clin Oncol 18, 3384–3389.
[19] Wilkowski R, Thoma M, Bruns C, Wagner A, and Heinemann V (2006). Che-
moradiotherapy with gemcitabine and continuous 5-FU in patients with prima-
ry inoperable pancreatic cancer. JOP 7, 349–360.
[20] Safran H, Dipetrillo T, Iannitti D, Quirk D, Akerman P, Cruff D, Cioffi W,
Shah S, Ramdin N, and Rich T (2002). Gemcitabine, paclitaxel, and radiation
for locally advanced pancreatic cancer: a phase I trial. Int J Radiat Oncol Biol
Phys 54, 137–141.
[21] Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC,
Bearden JD, Minotto DC, Howerton R, et al. (2005). Phase II trial of induction
Figure 4. The effects of gemcitabine and oxaliplatin on γ-H2AX in
response to radiation. (A) BxPC-3 or (B) Panc-1 cells were treated
with gemcitabine (0.3 or 1 μM, respectively) or oxaliplatin (3 or
10 μM, respectively) according to treatment schedule 1. At the end
of the treatment schedule, cells were treated with 8-Gy radiation.
Twenty-four hours postirradiation, cells were analyzed for γ-H2AX
by immunoblot analysis. Data are shown are from a single experi-
ment representative of three independent experiments.
42 Radiotherapy with Gemcitabine and Oxaliplatin Morgan et al. Translational Oncology Vol. 1, No. 1, 2008
gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and
concurrent external beam radiation for the treatment of locally advanced pan-
creatic cancer. Am J Clin Oncol 28, 345–350.
[22] Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ,
Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine com-
pared with gemcitabine alone in patients with advanced pancreatic cancer: a
phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol 25, 1960–1966.
[23] Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D,
Miner T, Martel D, Cioffi W, Remis M, et al. (1999). Erlotinib and chemo-
radiation followed by maintenance erlotinib for locally advanced pancreatic
cancer: a phase I study. Am J Clin Oncol 28, 570–575.
[24] Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K,
Charnsangavej C, Pisters PW, Lee JE, et al. (2001). Toxicity and efficacy of
concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Int J Pancreatol 29, 9–18.
[25] Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, Charn-
sangavej C, Pisters PW, Lenzi R, Papagikos MA, et al. (2001). Phase I study of
concomitant gemcitabine and IMRT for patients with unresectable adenocarci-
noma of the pancreatic head. Int J Gastrointest Cancer 30, 123–132.
[26] Scalliet P, Goor C, Galdermans D, Meerbeek JV, Groen HJ, Leest AHDVd,
Westerink H, Jungnelius U, and Turrisi L (1998). Gemcitabine with thoracic
radiotherapy—a phase II pilot study in chemonaive patients with advanced
non–small cell lung cancer. Proc Am Soc Clin Oncol 17, 499a. Abstract # 1923.
Translational Oncology Vol. 1, No. 1, 2008 Radiotherapy with Gemcitabine and Oxaliplatin Morgan et al. 43
